MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
2.260
-0.175
-7.19%
After Hours: 2.300 +0.04 +1.76% 19:53 02/06 EST
OPEN
2.475
PREV CLOSE
2.435
HIGH
2.500
LOW
2.230
VOLUME
7.93M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.7600
MARKET CAP
523.09M
P/E (TTM)
-3.2887
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK)
TipRanks · 3d ago
Weekly Report: what happened at GOSS last week (0126-0130)?
Weekly Report · 5d ago
GOSSAMER BIO INC : FILES FOR MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING
Reuters · 01/28 21:19
Gossamer Bio files automatic mixed securities shelf
TipRanks · 01/28 21:13
Gossamer Bio Initiated at Overweight by Barclays
Dow Jones · 01/28 14:45
Gossamer Bio Price Target Announced at $9.00/Share by Barclays
Dow Jones · 01/28 14:45
Barclays Initiates Coverage On Gossamer Bio with Overweight Rating, Announces Price Target of $9
Benzinga · 01/28 14:35
U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth
Reuters · 01/28 07:23
More
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.